Pack
4 tablet
1 tablet
6 tablet
Commissioned by NHSE
Pack
42 tablet
210 tablet
Pack
90 tablet
180 tablet
Pack
14 capsule
56 capsule
Pack
56 capsule
Pack
42 tablet (3 x 14 tablets)
210 tablet
Pack
90 tablet (6 x 15 tablets)
180 tablet (9 x 20 tablets)
Pack
14 capsule
Pack
56 capsule (2 x 28 capsules)

Commissioned by NHSE

Pack
28 capsule
Pack
7 capsule
28 capsule
Pack
28 capsule (2 x 14 capsules)
Pack
28 capsule (2 x 14 capsules)
7 capsule
Pack
4 pre-filled disposable injection
12 pre-filled disposable injection
Pack
6 pre-filled disposable injection
Pack
4 cartridge
Pack
6 pre-filled disposable injection
12 pre-filled disposable injection
Pack
4 cartridge
Pack
12 pre-filled disposable injection

Natalizumab (subcutaneous originator or intravenous biosimilar) can be used as an option to treat highly active relapsing–remitting multiple sclerosis (RRMS) in adults, only if:

  • it has not responded to a full and adequate course of at least 1 disease-modifying therapy OR
  • the characteristics of the person and the activity of their MS mean that cladribine is not suitable. (NICE TA1126)

Natalizumab (intravenous originator) 

  • Should NOT be used to treat highly active RRMS that has not responded to a full and adequate course of at least 1 disease-modifying therapy in adults. (NICE TA1126)
Pack
2 pre-filled disposable injection
Pack
1 vial
Pack
2 pre-filled disposable injection
Pack
1 vial
Commissioned by NHSE Multiple Sclerosis (relapsing–remitting)
Pack
28 tablet
Pack
28 tablet

For treating relapsing forms of multiple sclerosis, defined as active by clinical or imaging features in adults, only if:
 the multiple sclerosis is relapsing–remitting

Pack
1 Vial